Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1glp-1 receptor agonistscopdqjmobservational data

QJM commentary questions COPD respiratory benefits attributed to GLP-1 agonists

Authors argue phenotype channeling and the obesity paradox in COPD may confound observational findings of respiratory benefit.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 20:00 ETSource: QJM : monthly journal of the Association of Physicians

The wire

  1. 01A QJM piece by Cardenas-Duran and Lorences-Noguera argues that channeling by phenotype could confound reported respiratory benefits of GLP-1 receptor agonists in COPD.
  2. 02Clinicians citing observational COPD data when prescribing GLP-1s should weigh the possibility that healthier or differently phenotyped patients were selected for treatment.
  3. 03This is a commentary rather than new trial data, and it does not quantify the size of any confounding effect.

From the source

Channeling by Phenotype: Does the Obesity Paradox in COPD Confound the Respiratory Benefits Attributed to GLP-1 Receptor Agonists?

QJM : monthly journal of the Association of Physicians · 2026 Sep 17 · Cardenas-Duran E, Lorences-Noguera H et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42755054/